Agency Information Collection Activities; Proposed Collection; Comment Request; Focus Groups as Used by the Food and Drug Administration (All Food and Drug Administration-Regulated Products), 18763-18765 [2017-08065]
Download as PDF
Federal Register / Vol. 82, No. 76 / Friday, April 21, 2017 / Notices
FEDERAL RESERVE SYSTEM
sradovich on DSK3GMQ082PROD with NOTICES
Formations of, Acquisitions by, and
Mergers of Savings and Loan Holding
Companies
The companies listed in this notice
have applied to the Board for approval,
pursuant to the Home Owners’ Loan Act
(12 U.S.C. 1461 et seq.) (HOLA),
Regulation LL (12 CFR part 238), and
Regulation MM (12 CFR part 239), and
all other applicable statutes and
regulations to become a savings and
loan holding company and/or to acquire
the assets or the ownership of, control
of, or the power to vote shares of a
savings association and nonbanking
companies owned by the savings and
loan holding company, including the
companies listed below.
The applications listed below, as well
as other related filings required by the
Board, are available for immediate
inspection at the Federal Reserve Bank
indicated. The application also will be
available for inspection at the offices of
the Board of Governors. Interested
persons may express their views in
writing on the standards enumerated in
the HOLA (12 U.S.C. 1467a(e)). If the
proposal also involves the acquisition of
a nonbanking company, the review also
includes whether the acquisition of the
nonbanking company complies with the
standards in section 10(c)(4)(B) of the
HOLA (12 U.S.C. 1467a(c)(4)(B)). Unless
otherwise noted, nonbanking activities
will be conducted throughout the
United States.
Unless otherwise noted, comments
regarding each of these applications
must be received at the Reserve Bank
indicated or the offices of the Board of
Governors not later than May 15, 2017.
A. Federal Reserve Bank of
Philadelphia (William Spaniel, Senior
Vice President), 100 North 6th Street,
Philadelphia, Pennsylvania 19105–
1521. Comments can also be sent
electronically to
Comments.applications@phil.frb.org:
1. Ponce Bank Mutual Holding
Company, Bronx, New York and PDL
Community Bancorp, Bronx, New York;
to become savings and loan holding
companies, by acquiring 100 percent of
Ponce Bank, Bronx, New York, upon the
conversion of Ponce De Leon Federal
Bank, from a federal mutual savings
bank to a federal stock savings bank, to
be called Ponce Bank, both of Bronx,
New York.
Board of Governors of the Federal Reserve
System, April 17, 2017.
Margaret M. Shanks,
Deputy Secretary of the Board.
FEDERAL RETIREMENT THRIFT
INVESTMENT BOARD
Sunshine Act; Notice of Board Member
Meeting
Federal Retirement Thrift Investment
Board, 77 K Street NE., 10th Floor Board
Room, Washington, DC 20002.
FEDERAL REGISTER CITATION OF PREVIOUS
ANNOUNCEMENT: 82 FR 17991.
PREVIOUSLY ANNOUNCED TIME AND DATE OF
THE MEETING: 8:30 a.m., April 24, 2017.
CHANGES IN THE MEETING:
Time: 9 a.m.
Agenda
Federal Retirement Thrift Investment
Board Member Meeting, April 24, 2017,
9:00 a.m. (In-Person).
Open Session
1. Approval of the Meeting Minutes for
the March 27, 2017 Board Member
Meeting
2. Monthly Reports
(a) Participant Activity Report
(b) Legislative Report
3. Quarterly Reports
(c) Investment Performance
(d) Audit Status
4. OCFO Annual Report and Budget
Review
5. Internal Audit
6. Annual Financial Audit—CLA
7. DOL Presentation
8. Consolidated IT/Audit Activities
Closed Session
Information covered under 5 U.S.C.
552b(c)(9)(B).
Adjourn
CONTACT PERSON FOR MORE INFORMATION:
Kimberly Weaver, Director, Office of
External Affairs, (202) 942–1640.
Dated: April 19, 2017.
Megan Grumbine,
Secretary, Federal Retirement Thrift
Investment Board.
[FR Doc. 2017–08261 Filed 4–19–17; 4:15 pm]
BILLING CODE 6760–01–P
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
Food and Drug Administration
[Docket No. FDA–2010–N–0594]
Agency Information Collection
Activities; Proposed Collection;
Comment Request; Focus Groups as
Used by the Food and Drug
Administration (All Food and Drug
Administration-Regulated Products)
[FR Doc. 2017–08053 Filed 4–20–17; 8:45 am]
AGENCY:
BILLING CODE 6210–01–P
Food and Drug Administration,
HHS.
VerDate Sep<11>2014
17:30 Apr 20, 2017
Jkt 241001
PO 00000
Frm 00036
Fmt 4703
Sfmt 4703
ACTION:
18763
Notice.
The Food and Drug
Administration (FDA or Agency) is
announcing an opportunity for public
comment on the proposed collection of
certain information by the Agency.
Under the Paperwork Reduction Act of
1995 (PRA), Federal Agencies are
required to publish notice in the
Federal Register concerning each
proposed collection of information,
including each proposed extension of an
existing collection of information, and
to allow 60 days for public comment in
response to the notice. This notice
solicits comments on ‘‘Focus Groups as
Used by the Food and Drug
Administration (All FDA-Regulated
Products).’’
SUMMARY:
Submit either electronic or
written comments on the collection of
information by June 20, 2017. Late,
untimely filed comments will not be
considered. Electronic comments must
be submitted on or before June 20, 2017.
The https://www.regulations.gov
electronic filing system will accept
comments until midnight Eastern Time
at the end of June 20, 2017. Comments
received by mail/hand delivery/courier
(for written/paper submissions) will be
considered timely if they are
postmarked or the delivery service
acceptance receipt is on or before that
date.
ADDRESSES: You may submit comments
as follows:
DATES:
Electronic Submissions
Submit electronic comments in the
following way:
• Federal eRulemaking Portal:
https://www.regulations.gov. Follow the
instructions for submitting comments.
Comments submitted electronically,
including attachments, to https://
www.regulations.gov will be posted to
the docket unchanged. Because your
comment will be made public, you are
solely responsible for ensuring that your
comment does not include any
confidential information that you or a
third party may not wish to be posted,
such as medical information, your or
anyone else’s Social Security number, or
confidential business information, such
as a manufacturing process. Please note
that if you include your name, contact
information, or other information that
identifies you in the body of your
comments, that information will be
posted on https://www.regulations.gov.
• If you want to submit a comment
with confidential information that you
do not wish to be made available to the
public, submit the comment as a
written/paper submission and in the
E:\FR\FM\21APN1.SGM
21APN1
18764
Federal Register / Vol. 82, No. 76 / Friday, April 21, 2017 / Notices
manner detailed (see ‘‘Written/Paper
Submissions’’ and ‘‘Instructions’’).
Written/Paper Submissions
Submit written/paper submissions as
follows:
• Mail/Hand delivery/Courier (for
written/paper submissions): Division of
Dockets Management (HFA–305), Food
and Drug Administration, 5630 Fishers
Lane, Rm. 1061, Rockville, MD 20852.
• For written/paper comments
submitted to the Division of Dockets
Management, FDA will post your
comment, as well as any attachments,
except for information submitted,
marked and identified, as confidential,
if submitted as detailed in
‘‘Instructions.’’
Instructions: All submissions received
must include the Docket No. FDA–
2010–N–0594 for ‘‘Focus Groups as
Used by the Food and Drug
Administration (All FDA-Regulated
Products).’’ Received comments, those
filed in a timely manner (see DATES),
will be placed in the docket and, except
for those submitted as ‘‘Confidential
Submissions,’’ publicly viewable at
https://www.regulations.gov or at the
Division of Dockets Management
between 9 a.m. and 4 p.m., Monday
through Friday.
• Confidential Submissions—To
submit a comment with confidential
information that you do not wish to be
made publicly available, submit your
comments only as a written/paper
submission. You should submit two
copies total. One copy will include the
information you claim to be confidential
with a heading or cover note that states
‘‘THIS DOCUMENT CONTAINS
CONFIDENTIAL INFORMATION.’’ The
Agency will review this copy, including
the claimed confidential information, in
its consideration of comments. The
second copy, which will have the
claimed confidential information
redacted/blacked out, will be available
for public viewing and posted on
https://www.regulations.gov. Submit
both copies to the Division of Dockets
Management. If you do not wish your
name and contact information to be
made publicly available, you can
provide this information on the cover
sheet and not in the body of your
comments and you must identify this
information as ‘‘confidential.’’ Any
information marked as ‘‘confidential’’
will not be disclosed except in
accordance with 21 CFR 10.20 and other
applicable disclosure law. For more
information about FDA’s posting of
comments to public dockets, see 80 FR
56469, September 18, 2015, or access
the information at: https://www.gpo.gov/
fdsys/pkg/FR-2015-09-18/pdf/201523389.pdf.
Docket: For access to the docket to
read background documents or the
electronic and written/paper comments
received, go to https://
www.regulations.gov and insert the
docket number, found in brackets in the
heading of this document, into the
‘‘Search’’ box and follow the prompts
and/or go to the Division of Dockets
Management, 5630 Fishers Lane, Rm.
1061, Rockville, MD 20852.
FOR FURTHER INFORMATION CONTACT:
JonnaLynn Capezzuto, Office of
Operations, Food and Drug
Administration, Three White Flint
North 10A63, 11601 Landsdown St.,
North Bethesda, MD 20852, 301–796–
3794.
SUPPLEMENTARY INFORMATION: Under the
PRA (44 U.S.C. 3501–3520), Federal
Agencies must obtain approval from the
Office of Management and Budget
(OMB) for each collection of
information they conduct or sponsor.
‘‘Collection of information’’ is defined
in 44 U.S.C. 3502(3) and 5 CFR
1320.3(c) and includes Agency requests
or requirements that members of the
public submit reports, keep records, or
provide information to a third party.
Section 3506(c)(2)(A) of the PRA (44
U.S.C. 3506(c)(2)(A)) requires Federal
Agencies to provide a 60-day notice in
the Federal Register concerning each
proposed collection of information
before submitting the collection to OMB
for approval. To comply with this
requirement, FDA is publishing notice
of the proposed collection of
information set forth in this document.
With respect to the following
collection of information, FDA invites
comments on these topics: (1) Whether
the proposed collection of information
is necessary for the proper performance
of FDA’s functions, including whether
the information will have practical
utility; (2) the accuracy of FDA’s
estimate of the burden of the proposed
collection of information, including the
validity of the methodology and
assumptions used; (3) ways to enhance
the quality, utility, and clarity of the
information to be collected; and (4)
ways to minimize the burden of the
collection of information on
respondents, including through the use
of automated collection techniques,
when appropriate, and other forms of
information technology.
Focus Groups as Used by the Food and
Drug Administration (All FDARegulated Products) OMB Control
Number 0910–0497
FDA conducts focus group interviews
on a variety of topics involving FDAregulated products, including drugs,
biologics, devices, food, tobacco, and
veterinary medicine.
Focus groups provide an important
role in gathering information because
they allow for a more in-depth
understanding of patients’ and
consumers’ attitudes, beliefs,
motivations, and feelings than do
quantitative studies. Focus groups serve
the narrowly defined need for direct and
informal opinion on a specific topic and
as a qualitative research tool have three
major purposes:
• To obtain patient and consumer
information that is useful for developing
variables and measures for quantitative
studies,
• to better understand patients’ and
consumers’ attitudes and emotions in
response to topics and concepts, and
• to further explore findings obtained
from quantitative studies.
FDA will use focus group findings to
test and refine their ideas, but will
generally conduct further research
before making important decisions such
as adopting new policies and allocating
or redirecting significant resources to
support these policies.
FDA estimates the burden of this
collection of information as follows:
sradovich on DSK3GMQ082PROD with NOTICES
TABLE 1—ESTIMATED ANNUAL REPORTING BURDEN 1
Activity
Number
respondents
Annual
frequency per
response
Total annual
responses
Hours per
response
Total hours
Focus Group Interviews .......................................................
8,800
1
8,800
1.75
15,400
1 There
are no capital costs or operating and maintenance costs associated with this collection of information.
VerDate Sep<11>2014
17:30 Apr 20, 2017
Jkt 241001
PO 00000
Frm 00037
Fmt 4703
Sfmt 4703
E:\FR\FM\21APN1.SGM
21APN1
Federal Register / Vol. 82, No. 76 / Friday, April 21, 2017 / Notices
Dated: April 17, 2017.
Anna K. Abram,
Deputy Commissioner for Policy, Planning,
Legislation, and Analysis.
[FR Doc. 2017–08065 Filed 4–20–17; 8:45 am]
BILLING CODE 4164–01–P
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
Office of the Secretary
[CFDA–93.788]
Delegation of Authority to the
Assistant Secretary for Mental Health
and Substance Use
Notice is hereby given that I have
delegated to the Assistant Secretary for
Mental Health and Substance Use, or his
or her successor, the authorities vested
in the Secretary of the Department of
Health and Human Services, under Sec.
1003(a), (c), and (d) of the 21st Century
Cures Act to support the Opioid Grant
Program. This authority excludes the
authority to promulgate regulations and
to submit reports to Congress.
These authorities may be re-delegated.
I have ratified and affirmed any
actions taken by the Acting Deputy
Assistant Secretary for Mental Health
and Substance Use or by any
subordinates, which, in effect involved
the exercise of these authorities
delegated herein prior to the effective
date of this delegation. This delegation
was effective upon date of signature.
Dated: April 13, 2017.
Thomas E. Price,
Secretary.
[FR Doc. 2017–08050 Filed 4–20–17; 8:45 am]
BILLING CODE 4162–20–P
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
Office of the Secretary
sradovich on DSK3GMQ082PROD with NOTICES
Notice of Interest Rate on Overdue
Debts
Section 30.18 of the Department of
Health and Human Services’ claims
collection regulations (45 CFR part 30)
provides that the Secretary shall charge
an annual rate of interest, which is
determined and fixed by the Secretary
of the Treasury after considering private
consumer rates of interest on the date
that the Department of Health and
Human Services becomes entitled to
recovery. The rate cannot be lower than
the Department of Treasury’s current
value of funds rate or the applicable rate
determined from the ‘‘Schedule of
Certified Interest Rates with Range of
VerDate Sep<11>2014
17:30 Apr 20, 2017
Jkt 241001
Maturities’’ unless the Secretary waives
interest in whole or part, or a different
rate is prescribed by statute, contract, or
repayment agreement. The Secretary of
the Treasury may revise this rate
quarterly. The Department of Health and
Human Services publishes this rate in
the Federal Register.
The current rate of 10%, as fixed by
the Secretary of the Treasury, is certified
for the quarter ended March 31, 2017.
This rate is based on the Interest Rates
for Specific Legislation, ‘‘National
Health Services Corps Scholarship
Program (42 U.S.C. 254o(b)(1)(A))’’ and
‘‘National Research Service Award
Program (42 U.S.C. 288(c)(4)(B)).’’ This
interest rate will be applied to overdue
debt until the Department of Health and
Human Services publishes a revision.
Dated: April 11, 2017.
David C. Horn,
Director, Office of Financial Policy and
Reporting.
[FR Doc. 2017–08046 Filed 4–20–17; 8:45 am]
BILLING CODE 4150–04–P
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
Office of the Secretary
Opioids were responsible for over
33,000 deaths in 2015; this alarming
statistic is unacceptable. Through a
sustained focus on people, patients, and
partnerships, this crisis can be
addressed across our nation.
Last month President Trump
announced the President’s Commission
on Combating Drug Addiction and the
Opioid Crisis. This Commission is
tasked with studying the scope and
effectiveness of the federal response to
this crisis and providing
recommendations to the President for
improving it. As the Administration
develops a comprehensive strategy to
improve the federal response to combat
opioids, the U.S. Department of Health
and Human Services (HHS) must ensure
the Opioid State Targeted Response
grants are aligned accordingly and put
to the best use possible. Given the
urgency of the issue, we understand the
need to release the funding for the first
year of this program immediately.
However, the intentions of HHS for the
second year are to develop funding
allocations and policies that are the
most clinically sound, effective and
efficient.
In the interest of ensuring that these
resources are applied in the best manner
possible, I will be seeking input from
Frm 00038
Fmt 4703
Sfmt 4703
the states/territories in the coming
weeks and months. As funding from the
first year is implemented and
monitored, states/territories will be
asked to identify best practices, lessons
learned, and key strategies that can help
HHS further target these funds in the
subsequent year to best address this
tragic issue.
Dated: April 13, 2017.
Thomas E. Price,
Secretary.
[FR Doc. 2017–08068 Filed 4–20–17; 8:45 am]
BILLING CODE 4162–20–P
DEPARTMENT OF HOMELAND
SECURITY
U.S. Citizenship and Immigration
Services
[OMB Control Number 1615–0008]
Agency Information Collection
Activities; Extension, Without Change,
of a Currently Approved Collection:
Discretionary Options for Designated
Spouses, Parents, and Sons and
Daughters of Certain Military
Personnel, Veterans, and Enlistees
U.S. Citizenship and
Immigration Services, Department of
Homeland Security.
ACTION: 60-Day notice.
AGENCY:
Opioid State Targeted Response
Grants
PO 00000
18765
The Department of Homeland
Security (DHS), U.S. Citizenship and
Immigration (USCIS) invites the general
public and other Federal agencies to
comment upon this proposed extension
of a currently approved collection of
information. In accordance with the
Paperwork Reduction Act (PRA) of
1995, the information collection notice
is published in the Federal Register to
obtain comments regarding the nature of
the information collection, the
categories of respondents, the estimated
burden (i.e. the time, effort, and
resources used by the respondents to
respond), the estimated cost to the
respondent, and the actual information
collection instruments.
DATES: Comments are encouraged and
will be accepted for 60 days until June
20, 2017.
ADDRESSES: All submissions received
must include the OMB Control Number
1615–0008 in the body of the letter, the
agency name and Docket ID USCIS–
2005–0024. To avoid duplicate
submissions, please use only one of the
following methods to submit comments:
(1) Online. Submit comments via the
Federal eRulemaking Portal Web site at
https://www.regulations.gov under eDocket ID number USCIS–2005–0024;
SUMMARY:
E:\FR\FM\21APN1.SGM
21APN1
Agencies
[Federal Register Volume 82, Number 76 (Friday, April 21, 2017)]
[Notices]
[Pages 18763-18765]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: 2017-08065]
=======================================================================
-----------------------------------------------------------------------
DEPARTMENT OF HEALTH AND HUMAN SERVICES
Food and Drug Administration
[Docket No. FDA-2010-N-0594]
Agency Information Collection Activities; Proposed Collection;
Comment Request; Focus Groups as Used by the Food and Drug
Administration (All Food and Drug Administration-Regulated Products)
AGENCY: Food and Drug Administration, HHS.
ACTION: Notice.
-----------------------------------------------------------------------
SUMMARY: The Food and Drug Administration (FDA or Agency) is announcing
an opportunity for public comment on the proposed collection of certain
information by the Agency. Under the Paperwork Reduction Act of 1995
(PRA), Federal Agencies are required to publish notice in the Federal
Register concerning each proposed collection of information, including
each proposed extension of an existing collection of information, and
to allow 60 days for public comment in response to the notice. This
notice solicits comments on ``Focus Groups as Used by the Food and Drug
Administration (All FDA-Regulated Products).''
DATES: Submit either electronic or written comments on the collection
of information by June 20, 2017. Late, untimely filed comments will not
be considered. Electronic comments must be submitted on or before June
20, 2017. The https://www.regulations.gov electronic filing system will
accept comments until midnight Eastern Time at the end of June 20,
2017. Comments received by mail/hand delivery/courier (for written/
paper submissions) will be considered timely if they are postmarked or
the delivery service acceptance receipt is on or before that date.
ADDRESSES: You may submit comments as follows:
Electronic Submissions
Submit electronic comments in the following way:
Federal eRulemaking Portal: https://www.regulations.gov.
Follow the instructions for submitting comments. Comments submitted
electronically, including attachments, to https://www.regulations.gov
will be posted to the docket unchanged. Because your comment will be
made public, you are solely responsible for ensuring that your comment
does not include any confidential information that you or a third party
may not wish to be posted, such as medical information, your or anyone
else's Social Security number, or confidential business information,
such as a manufacturing process. Please note that if you include your
name, contact information, or other information that identifies you in
the body of your comments, that information will be posted on https://www.regulations.gov.
If you want to submit a comment with confidential
information that you do not wish to be made available to the public,
submit the comment as a written/paper submission and in the
[[Page 18764]]
manner detailed (see ``Written/Paper Submissions'' and
``Instructions'').
Written/Paper Submissions
Submit written/paper submissions as follows:
Mail/Hand delivery/Courier (for written/paper
submissions): Division of Dockets Management (HFA-305), Food and Drug
Administration, 5630 Fishers Lane, Rm. 1061, Rockville, MD 20852.
For written/paper comments submitted to the Division of
Dockets Management, FDA will post your comment, as well as any
attachments, except for information submitted, marked and identified,
as confidential, if submitted as detailed in ``Instructions.''
Instructions: All submissions received must include the Docket No.
FDA-2010-N-0594 for ``Focus Groups as Used by the Food and Drug
Administration (All FDA-Regulated Products).'' Received comments, those
filed in a timely manner (see DATES), will be placed in the docket and,
except for those submitted as ``Confidential Submissions,'' publicly
viewable at https://www.regulations.gov or at the Division of Dockets
Management between 9 a.m. and 4 p.m., Monday through Friday.
Confidential Submissions--To submit a comment with
confidential information that you do not wish to be made publicly
available, submit your comments only as a written/paper submission. You
should submit two copies total. One copy will include the information
you claim to be confidential with a heading or cover note that states
``THIS DOCUMENT CONTAINS CONFIDENTIAL INFORMATION.'' The Agency will
review this copy, including the claimed confidential information, in
its consideration of comments. The second copy, which will have the
claimed confidential information redacted/blacked out, will be
available for public viewing and posted on https://www.regulations.gov.
Submit both copies to the Division of Dockets Management. If you do not
wish your name and contact information to be made publicly available,
you can provide this information on the cover sheet and not in the body
of your comments and you must identify this information as
``confidential.'' Any information marked as ``confidential'' will not
be disclosed except in accordance with 21 CFR 10.20 and other
applicable disclosure law. For more information about FDA's posting of
comments to public dockets, see 80 FR 56469, September 18, 2015, or
access the information at: https://www.gpo.gov/fdsys/pkg/FR-2015-09-18/pdf/2015-23389.pdf.
Docket: For access to the docket to read background documents or
the electronic and written/paper comments received, go to https://www.regulations.gov and insert the docket number, found in brackets in
the heading of this document, into the ``Search'' box and follow the
prompts and/or go to the Division of Dockets Management, 5630 Fishers
Lane, Rm. 1061, Rockville, MD 20852.
FOR FURTHER INFORMATION CONTACT: JonnaLynn Capezzuto, Office of
Operations, Food and Drug Administration, Three White Flint North
10A63, 11601 Landsdown St., North Bethesda, MD 20852, 301-796-3794.
SUPPLEMENTARY INFORMATION: Under the PRA (44 U.S.C. 3501-3520), Federal
Agencies must obtain approval from the Office of Management and Budget
(OMB) for each collection of information they conduct or sponsor.
``Collection of information'' is defined in 44 U.S.C. 3502(3) and 5 CFR
1320.3(c) and includes Agency requests or requirements that members of
the public submit reports, keep records, or provide information to a
third party. Section 3506(c)(2)(A) of the PRA (44 U.S.C. 3506(c)(2)(A))
requires Federal Agencies to provide a 60-day notice in the Federal
Register concerning each proposed collection of information before
submitting the collection to OMB for approval. To comply with this
requirement, FDA is publishing notice of the proposed collection of
information set forth in this document.
With respect to the following collection of information, FDA
invites comments on these topics: (1) Whether the proposed collection
of information is necessary for the proper performance of FDA's
functions, including whether the information will have practical
utility; (2) the accuracy of FDA's estimate of the burden of the
proposed collection of information, including the validity of the
methodology and assumptions used; (3) ways to enhance the quality,
utility, and clarity of the information to be collected; and (4) ways
to minimize the burden of the collection of information on respondents,
including through the use of automated collection techniques, when
appropriate, and other forms of information technology.
Focus Groups as Used by the Food and Drug Administration (All FDA-
Regulated Products) OMB Control Number 0910-0497
FDA conducts focus group interviews on a variety of topics
involving FDA-regulated products, including drugs, biologics, devices,
food, tobacco, and veterinary medicine.
Focus groups provide an important role in gathering information
because they allow for a more in-depth understanding of patients' and
consumers' attitudes, beliefs, motivations, and feelings than do
quantitative studies. Focus groups serve the narrowly defined need for
direct and informal opinion on a specific topic and as a qualitative
research tool have three major purposes:
To obtain patient and consumer information that is useful
for developing variables and measures for quantitative studies,
to better understand patients' and consumers' attitudes
and emotions in response to topics and concepts, and
to further explore findings obtained from quantitative
studies.
FDA will use focus group findings to test and refine their ideas,
but will generally conduct further research before making important
decisions such as adopting new policies and allocating or redirecting
significant resources to support these policies.
FDA estimates the burden of this collection of information as
follows:
Table 1--Estimated Annual Reporting Burden \1\
--------------------------------------------------------------------------------------------------------------------------------------------------------
Annual
Activity Number frequency per Total annual Hours per Total hours
respondents response responses response
--------------------------------------------------------------------------------------------------------------------------------------------------------
Focus Group Interviews............................................. 8,800 1 8,800 1.75 15,400
--------------------------------------------------------------------------------------------------------------------------------------------------------
\1\ There are no capital costs or operating and maintenance costs associated with this collection of information.
[[Page 18765]]
Dated: April 17, 2017.
Anna K. Abram,
Deputy Commissioner for Policy, Planning, Legislation, and Analysis.
[FR Doc. 2017-08065 Filed 4-20-17; 8:45 am]
BILLING CODE 4164-01-P